Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-071776
Filing Date
2026-02-25
Accepted
2026-02-25 16:31:17
Documents
126
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K inva-20251231.htm   iXBRL 10-K 5843831
2 EX-21.1 inva-ex21_1.htm EX-21.1 35276
3 EX-23.1 inva-ex23_1.htm EX-23.1 4560
4 EX-31.1 inva-ex31_1.htm EX-31.1 15969
5 EX-31.2 inva-ex31_2.htm EX-31.2 15040
6 EX-32 inva-ex32.htm EX-32 17648
7 GRAPHIC img75897552_0.jpg GRAPHIC 470675
8 GRAPHIC img75897552_1.gif GRAPHIC 84540
9 GRAPHIC img75897552_2.jpg GRAPHIC 58649
10 GRAPHIC img75897552_3.jpg GRAPHIC 369446
11 GRAPHIC img75897552_4.gif GRAPHIC 127941
12 GRAPHIC img75897552_5.jpg GRAPHIC 107501
13 GRAPHIC img75897552_6.gif GRAPHIC 65104
14 GRAPHIC img75897552_7.jpg GRAPHIC 322272
15 GRAPHIC img75897552_8.gif GRAPHIC 86736
16 GRAPHIC img75897552_9.jpg GRAPHIC 581477
17 GRAPHIC img75897552_10.jpg GRAPHIC 79740
18 GRAPHIC img75897552_11.jpg GRAPHIC 549110
19 GRAPHIC img75897552_12.jpg GRAPHIC 226944
20 GRAPHIC img75897552_13.gif GRAPHIC 41366
21 GRAPHIC img75897552_14.gif GRAPHIC 32316
22 GRAPHIC img75897552_15.gif GRAPHIC 29195
23 GRAPHIC img75897552_16.jpg GRAPHIC 85663
24 GRAPHIC img75897552_17.jpg GRAPHIC 204435
25 GRAPHIC img75897552_18.jpg GRAPHIC 168277
26 GRAPHIC img75897552_19.gif GRAPHIC 182141
  Complete submission text file 0001193125-26-071776.txt   32642512

Data Files

Seq Description Document Type Size
27 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inva-20251231.xsd EX-101.SCH 2887296
129 EXTRACTED XBRL INSTANCE DOCUMENT inva-20251231_htm.xml XML 4829660
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-30319 | Film No.: 26679272
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)